Psychological impact of pancreatic cancer screening by EUS or magnetic resonance imaging in high-risk individuals: A systematic review

Irina Mihaela Cazacu, Adriana Alexandra Luzuriaga Chavez, Adrian Saftoiu, Manoop S Bhutani, Irina Mihaela Cazacu, Adriana Alexandra Luzuriaga Chavez, Adrian Saftoiu, Manoop S Bhutani

Abstract

Background and objectives: There is an increasing global interest in screening programs aiming to detect pancreatic cancer (PC) in an early and potentially curable stage. Concerns still remain as to whether screening would confer any survival benefit. Another approach to evaluate the benefits of the pancreatic screening programs would be to consider its impact on the quality of life of the individuals who at risk of developing cancer. The aim of this systematic review was to investigate the current knowledge regarding the psychological impact of participation in routine screening for PC.

Methods: A systematic literature search was carried out in January 2018 in three major databases which are as follows: PubMed, Scopus, and Web of Science. Cross-sectional and prospective studies evaluating the psychological aspects of screening in high-risk individuals were included in the study. For each study, the following data were recorded: name of first author, year of publication, study design, study population, aims, screening protocol, outcomes and instruments, main results, and summary of findings.

Results: Six cohort studies and one cross-sectional study that addressed the psychological aspects of PC screening were included in the analysis. Overall, studies have shown that high-risk individuals have positive psychological outcomes from participating in PC screening programs.

Conclusions: Although screening might not always be reassuring, it may improve individuals' quality of life, and this should be an important aspect when considering PC screening.

Keywords: EUS; pancreatic cancer; quality of life; screening.

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Flow diagram-search strategy

References

    1. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.
    1. SEER Cancer Stat Facts: pancreas Cancer. National Cancer Institute. [Last accessed on 2018 Mar 13]. Available from: .
    1. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–89.
    1. Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol. 2015;42:8–18.
    1. Canto MI, Harinck F, Hruban RH, et al. International cancer of the pancreas screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62:339–47.
    1. Brentnall TA, Bronner MP, Byrd DR, et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 1999;131:247–55.
    1. Vasen H, Ibrahim I, Ponce CG, et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: Outcome of long-term prospective follow-up studies from three european expert centers. J Clin Oncol. 2016;34:2010–9.
    1. Al-Sukhni W, Borgida A, Rothenmund H, et al. Screening for pancreatic cancer in a high-risk cohort: An eight-year experience. J Gastrointest Surg. 2012;16:771–83.
    1. Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142:796–804.
    1. DaVee T, Coronel E, Papafragkakis C, et al. Pancreatic cancer screening in high-risk individuals with germline genetic mutations. Gastrointest Endosc. 2018;87:1443–50.
    1. Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol. 2011;106:946–54.
    1. Vasen HF. The importance of a well-structured pancreatic screening program for familial and hereditary pancreatic cancer. Fam Cancer. 2018;17:1–3.
    1. Hutton J, Walker LG, Gilbert FJ, et al. Psychological impact and acceptability of magnetic resonance imaging and X-ray mammography: The MARIBS study. Br J Cancer. 2011;104:578–86.
    1. Wardle J, Williamson S, Sutton S, et al. Psychological impact of colorectal cancer screening. Health Psychol. 2003;22:54–9.
    1. Maheu C, Vodermaier A, Rothenmund H, et al. Pancreatic cancer risk counselling and screening: Impact on perceived risk and psychological functioning. Fam Cancer. 2010;9:617–24.
    1. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
    1. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses [Ottawa Hospital Research Institute, 2011] [Last accessed 2018 Jan 29]. Available from: .
    1. Hart SL, Torbit LA, Crangle CJ, et al. Moderators of cancer-related distress and worry after a pancreatic cancer genetic counseling and screening intervention. Psychooncology. 2012;21:1324–30.
    1. Harinck F, Nagtegaal T, Kluijt I, et al. Feasibility of a pancreatic cancer surveillance program from a psychological point of view. Genet Med. 2011;13:1015–24.
    1. Konings IC, Sidharta GN, Harinck F, et al. Repeated participation in pancreatic cancer surveillance by high-risk individuals imposes low psychological burden. Psychooncology. 2016;25:971–8.
    1. Konings IC, Harinck F, Kuenen MA, et al. Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance. Fam Cancer. 2017;16:143–51.
    1. McBride KA, Ballinger ML, Schlub TE, et al. Psychosocial morbidity in TP53 mutation carriers: Is whole-body cancer screening beneficial? Fam Cancer. 2017;16:423–32.
    1. McKay S, Gunasingam N, Meiser B, et al. Pancreatic cancer screening in high risk individuals does not have negative psychological impact in the short or long term. Gastroenterology. 2017;152:S277.
    1. Lerman C, Trock B, Rimer BK, et al. Psychological side effects of breast cancer screening. Health Psychol. 1991;10:259–67.
    1. Gopie JP, Vasen HF, Tibben A. Surveillance for hereditary cancer: Does the benefit outweigh the psychological burden? – A systematic review. Crit Rev Oncol Hematol. 2012;83:329–40.
    1. Horowitz M, Wilner N, Alvarez W. Impact of event scale: A measure of subjective stress. Psychosom Med. 1979;41:209–18.
    1. Joseph S. Psychometric evaluation of Horowitz's impact of event scale: A review. J Trauma Stress. 2000;13:101–13.
    1. Douma KF, Aaronson NK, Vasen HF, et al. Psychological distress and use of psychosocial support in familial adenomatous polyposis. Psychooncology. 2010;19:289–98.
    1. Bjelland I, Dahl AA, Haug TT, et al. The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res. 2002;52:69–77.
    1. Spinhoven P, Ormel J, Sloekers PP, et al. A validation study of the hospital anxiety and depression scale (HADS) in different groups of dutch subjects. Psychol Med. 1997;27:363–70.
    1. de Graaf R, ten Have M, van Gool C, et al. Prevalence of mental disorders and trends from 1996 to 2009. Results from the Netherlands Mental Health Survey and Incidence Study-2. Soc Psychiatry Psychiatr Epidemiol. 2012;47:203–13.
    1. Derogatis LR, Melisaratos N. The brief symptom inventory: An introductory report. Psychol Med. 1983;13:595–605.
    1. Cockburn J, De Luise T, Hurley S, et al. Development and validation of the PCQ: A questionnaire to measure the psychological consequences of screening mammography. Soc Sci Med. 1992;34:1129–34.
    1. Underhill M, Berry D, Dalton E, et al. Patient experiences living with pancreatic cancer risk. Hered Cancer Clin Pract. 2015;13:13.
    1. Breitkopf CR, Sinicrope PS, Rabe KG, et al. Factors influencing receptivity to future screening options for pancreatic cancer in those with and without pancreatic cancer family history. Hered Cancer Clin Pract. 2012;10:8.
    1. Howell LA, Sinicrope PS, Brockman TA, et al. Receptivity and preferences of pancreatic cancer family members for participating in lifestyle programs to reduce cancer risk. Hered Cancer Clin Pract. 2013;11:3.
    1. Lawson PJ, Flocke SA. Teachable moments for health behavior change: A concept analysis. Patient Educ Couns. 2009;76:25–30.
    1. Radecki Breitkopf C, Asiedu GB, Egginton J, et al. An investigation of the colorectal cancer experience and receptivity to family-based cancer prevention programs. Support Care Cancer. 2014;22:2517–25.
    1. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: A prospective controlled study. Clin Gastroenterol Hepatol. 2006;4:766–81.
    1. Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol. 2009;104:2175–81.
    1. Lewis ZK, Frost CJ, Venne VL. Pancreatic cancer surveillance among high-risk populations: Knowledge and intent. J Genet Couns. 2009;18:229–38.
    1. Claes E, Denayer L, Evers-Kiebooms G, et al. Predictive testing for hereditary non-polyposis colorectal cancer: Motivation, illness representations and short-term psychological impact. Patient Educ Couns. 2004;55:265–74.
    1. Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut. 2009;58:1410–8.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe